List of Excipients in Branded Drug EDARBYCLOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	EDARBYCLOR	azilsartan kamedoxomil and chlorthalidone	60631-412	ALCOHOL
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	EDARBYCLOR	azilsartan kamedoxomil and chlorthalidone	60631-412	BUTYL ALCOHOL
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	EDARBYCLOR	azilsartan kamedoxomil and chlorthalidone	60631-412	CELLULOSE, MICROCRYSTALLINE
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	EDARBYCLOR	azilsartan kamedoxomil and chlorthalidone	60631-412	CROSPOVIDONE

EDARBYCLOR Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

EDARBYCLOR is a fixed-dose antihypertensive combining azilsartan medoxomil and chlorthalidone. Its excipient platform is conventional for an immediate-release tablet: a polyol diluent, cellulose-based filler, superdisintegrant, binder, and lubricant. The strongest commercial opportunities are in generic development, excipient substitution, process optimization, dose-ratio extensions, and differentiated packaging rather than in novel excipient technology.

The principal development constraint is the drug product itself. Azilsartan medoxomil has limited aqueous solubility, while chlorthalidone is a potent, low-dose diuretic. A successful product must control blend uniformity, tablet weight, dissolution, content uniformity, and moisture exposure across the combined dose strengths.

What is EDARBYCLOR and how is it formulated?

EDARBYCLOR is an oral, once-daily fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker, and chlorthalidone, a thiazide-like diuretic. The FDA-approved strengths are:

Product strength	Azilsartan medoxomil	Chlorthalidone
EDARBYCLOR 40/12.5 mg	40 mg	12.5 mg
EDARBYCLOR 40/25 mg	40 mg	25 mg
EDARBYCLOR 80/12.5 mg	80 mg	12.5 mg
EDARBYCLOR 80/25 mg	80 mg	25 mg

The product is manufactured as an immediate-release tablet. The combination is intended for patients who require additional blood-pressure reduction after treatment with azilsartan medoxomil or chlorthalidone alone. FDA labeling identifies the product as a Takeda Pharmaceuticals USA product approved in 2011.[1]

What excipients are used in EDARBYCLOR?

The FDA labeling identifies the core inactive ingredients as mannitol, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate.[1] The formulation uses a standard direct-compression or dry-granulation-type excipient architecture, although the commercial manufacturing process must be confirmed from the relevant regulatory filing.

Excipient	Primary formulation role	Strategic relevance
Mannitol	Diluent, mouthfeel modifier, bulking agent	Supports tablet mass and may improve sensory properties
Microcrystalline cellulose	Diluent and dry binder	Improves compactibility and mechanical strength
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup and dissolution
Povidone	Binder	Supports granule or tablet cohesion
Magnesium stearate	Lubricant	Controls ejection force and tooling friction

The formulation is relatively accessible from a generic-development perspective because it does not depend on a proprietary lipid system, complex coating technology, or a novel excipient. The main technical challenge is achieving equivalent performance with a low-dose, high-potency component and a poorly soluble active pharmaceutical ingredient.

How does the EDARBYCLOR excipient system support product performance?

Why is mannitol important in EDARBYCLOR?

Mannitol provides bulk while maintaining a relatively low-hygroscopicity profile compared with some alternative polyols. It can support tablet hardness and improve the mouthfeel of an uncoated or lightly coated dosage form. Its commercial value is strongest where manufacturers want a robust, familiar diluent with a broad supplier base.

Mannitol grade selection can affect:

• Particle-size distribution
• Flow through the tablet press
• Compactability
• Tablet porosity
• Disintegration time
• Dissolution reproducibility

A generic manufacturer should avoid treating mannitol as an interchangeable commodity. Spray-dried, granular, and crystalline grades can produce materially different compression and dissolution behavior.

What role does microcrystalline cellulose play?

Microcrystalline cellulose is likely the principal structural filler and dry binder. It supports tablet strength at relatively modest compression forces and can compensate for poor compactability from the active ingredients.

The main risks are excessive lubricant sensitivity, over-compression, and delayed disintegration. High levels of microcrystalline cellulose can also change water uptake and dissolution behavior. Grade selection should be linked to particle size, bulk density, and compressibility rather than price alone.

Why is crospovidone used?

Crospovidone provides rapid wicking and tablet breakup. This is important because azilsartan medoxomil has limited intrinsic solubility. Disintegration alone does not guarantee rapid dissolution, but it increases the surface area available for wetting and dissolution.

Crospovidone level, particle size, and intra- versus extra-granular placement can influence:

• Disintegration time
• Initial dissolution
• Tablet friability
• Blend segregation
• Compression behavior

For a generic applicant, crospovidone substitution with croscarmellose sodium or sodium starch glycolate is possible in principle, but it increases formulation-development and bioequivalence risk. The substitute must preserve the dissolution profile across all four strengths.

What is the function of povidone?

Povidone acts as a binder and may improve cohesion in a formulation containing low-dose chlorthalidone. Its molecular-weight grade affects binding strength, viscosity, hygroscopicity, and granule behavior.

Excessive binder can reduce porosity and slow dissolution. Insufficient binder can produce friability, capping, or weight loss during coating and packaging. Povidone is therefore a process-control excipient rather than a simple inactive ingredient.

Why is magnesium stearate commercially important?

Magnesium stearate reduces friction during compression and tablet ejection. Over-lubrication can create a hydrophobic film around particles, reducing wetting and slowing dissolution.

A robust control strategy should specify:

• Lubricant concentration
• Lubrication time
• Blender shear
• Addition sequence
• Blend residence time
• Ejection force
• Dissolution impact

This is a likely source of process differentiation for generic manufacturers. Two products using the same nominal excipients can produce different release profiles because of lubrication and compression conditions.

What excipient risks are most important for generic EDARBYCLOR?

The main risks are formulation interaction and process sensitivity rather than excipient toxicity.

Risk	Likely impact	Mitigation
Azilsartan medoxomil poor solubility	Slow or variable dissolution	Optimize particle size, disintegration, wetting, and compression
Low chlorthalidone dose	Content-uniformity failure	Use controlled premixing, geometric dilution, or granulation
Blend segregation	Strength-to-strength variability	Match particle-size distribution and bulk density
Over-lubrication	Delayed dissolution	Control magnesium stearate mixing time and shear
Excessive compression	Reduced porosity and slower release	Establish compression-force design space
Moisture exposure	Stability or flow changes	Use moisture-controlled processing and protective packaging
Excipient grade changes	BE or dissolution variability	Qualify grades and suppliers under change-control procedures

Chlorthalidone is present at 12.5 mg or 25 mg, while the tablet may contain a materially larger amount of excipient. This creates a dilution problem. A formulation that is acceptable for the 80/25 mg strength may not transfer directly to the 40/12.5 mg strength without demonstrating blend uniformity and dissolution equivalence.

What formulation strategies could improve EDARBYCLOR?

Can excipient substitution create a differentiated generic?

Yes, but the commercial value depends on the regulatory pathway and the resulting product claim. The most practical substitutions are:

1. Replacing mannitol with an alternative directly compressible diluent.
2. Replacing crospovidone with another superdisintegrant.
3. Using silicified microcrystalline cellulose to improve flow and compactability.
4. Introducing a wetting aid or surfactant at a low level.
5. Using co-processed excipients to reduce manufacturing steps.

Substitution can lower cost or improve manufacturability, but it does not automatically create market exclusivity. For an ANDA, the applicant must establish pharmaceutical equivalence and bioequivalence. A materially different formulation may require additional comparative dissolution work and may complicate waiver arguments for lower strengths.

Is a solubility-enhanced EDARBYCLOR formulation commercially attractive?

Potentially. Azilsartan medoxomil is a prodrug with limited aqueous solubility, so a solubility-enhanced formulation could improve dissolution robustness. Relevant approaches include:

• Particle-size reduction
• Amorphous dispersion
• Surfactant-assisted wetting
• Co-processed carrier systems
• Solid-state modification
• Spray-dried intermediate systems

The commercial value would be highest if the formulation improves food-effect robustness, reduces tablet size, or supports a lower-cost manufacturing process. The regulatory burden would increase if the formulation changes the drug substance physical form or creates a new release profile.

Can EDARBYCLOR be developed as a smaller tablet?

Yes. Tablet-size reduction could improve adherence, particularly because the product combines two therapies that otherwise may be administered as separate tablets. The strongest options are higher-density excipient systems, optimized compression, and reduced excipient overage.

A smaller tablet must still meet hardness, friability, disintegration, dissolution, and content-uniformity requirements. Tablet miniaturization is more feasible for the 40/12.5 mg strength than for the 80/25 mg strength because the latter contains twice the amount of each active ingredient relative to the lowest strength.

What commercial opportunities exist for EDARBYCLOR excipient suppliers?

Which excipient categories have the largest opportunity?

The largest opportunities are in performance-grade excipients rather than commodity supply alone.

Excipient category	Opportunity	Buyer priority
Direct-compression mannitol	Better flow and compactability	High
Low-moisture microcrystalline cellulose	Stability and process consistency	High
Co-processed filler-binder systems	Fewer manufacturing steps	Medium to high
High-performance crospovidone	Faster disintegration and dissolution	High
Low-peroxide povidone	Oxidative stability control	Medium
Magnesium stearate with controlled surface properties	Consistent lubrication	Medium
Packaging-compatible moisture barriers	Stability protection	High

An excipient supplier can gain commercial leverage by providing formulation-development support, not only raw material. Comparative data showing dissolution performance, compression behavior, and scale-up reproducibility would be more valuable than a simple material substitution claim.

What contract manufacturing opportunities exist?

EDARBYCLOR is suitable for contract development and manufacturing organizations with:

• Potent-low-dose blending capability
• Immediate-release tablet compression
• Multi-strength product-line management
• High-shear or dry-granulation capacity
• Robust content-uniformity testing
• Moisture-controlled packaging operations

A CDMO can differentiate through a platform process that handles all four dose strengths with common excipient grades and limited tooling changes. The strongest cost advantage would come from reducing separate blend preparation and minimizing product changeover.

What patent and exclusivity issues affect EDARBYCLOR?

When did EDARBYCLOR lose regulatory exclusivity?

EDARBYCLOR received FDA approval in 2011. The product’s five-year new chemical entity exclusivity period would have expired in 2016, assuming the FDA treated the combination under the applicable NCE framework. Any later market protection would have depended on listed patents, pediatric exclusivity, or other regulatory provisions.[1,2]

The commercial entry question is therefore primarily patent- and litigation-driven, not NCE-exclusivity-driven.

What patents protect EDARBYCLOR?

Protection may arise from several layers:

• Azilsartan medoxomil composition patents
• The azilsartan medoxomil/chlorthalidone combination
• Dose-ratio claims
• Treatment methods for hypertension
• Tablet or formulation claims
• Manufacturing processes
• Regulatory exclusivities linked to pediatric studies

Orange Book patent status must be checked against the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database and the product’s patent listing history.[2] Patent expiration dates should not be inferred solely from the original filing date because patent-term adjustment, terminal disclaimers, and pediatric extensions can change the effective date.

What Paragraph IV challenges and litigation affect EDARBYCLOR?

An ANDA applicant seeking approval before listed patents expire may file a Paragraph IV certification. That can trigger patent litigation under the Hatch-Waxman framework and a potential 30-month stay of approval under applicable statutory conditions.[3]

The principal litigation variables are:

• Whether any EDARBYCLOR patents remain listed
• Whether the listed claims cover the proposed generic formulation
• Whether a challenger uses a section viii carve-out for method-of-use claims
• Whether the patent holder sues within the statutory period
• Whether the parties reach a settlement with a licensed or agreed entry date

A commercial diligence review should distinguish between patent validity, infringement, and FDA approval timing. A weak formulation patent may still delay entry if it is properly listed and litigated.

What is the FDA and Orange Book status of EDARBYCLOR?

EDARBYCLOR is an FDA-approved prescription fixed-dose combination tablet. The Orange Book is the controlling source for therapeutic-equivalence ratings, listed patents, exclusivity, and approved dosage forms.[2]

For commercial planning, the relevant checks are:

Regulatory item	Commercial implication
Approved dosage form	Immediate-release oral tablet pathway
Reference listed drug	Determines ANDA reference product
Listed patents	Determines Paragraph IV and section viii strategy
Therapeutic-equivalence code	Determines substitutability after approval
Exclusivity status	Determines timing of ANDA approval
Strengths	Determines formulation and bioequivalence package

A generic sponsor should evaluate whether each strength can be supported by comparative dissolution and a single pharmacokinetic study or whether additional studies are needed. The highest risk is usually not the existence of four strengths, but the ability to demonstrate consistent proportionality and manufacturing control across them.

How does EDARBYCLOR compare with competing antihypertensive combinations?

EDARBYCLOR competes with other ARB/thiazide combinations, including azilsartan medoxomil/chlorthalidone alternatives and products combining losartan, valsartan, olmesartan, or irbesartan with hydrochlorothiazide.

Product class	Differentiating factor	Excipient opportunity
Azilsartan/chlorthalidone	Potent ARB plus long-acting diuretic	Dissolution and low-dose uniformity
ARB/hydrochlorothiazide	Broad generic availability	Lowest-cost manufacturing
ARB/indapamide	Diuretic differentiation	Smaller tablet and sustained adherence
ARB alone plus separate diuretic	Flexible dose titration	Co-packaging and adherence programs

EDARBYCLOR’s commercial proposition is a fixed-dose combination that may reduce pill burden. Its disadvantage is competition from low-cost generic ARB/thiazide combinations and separate-tablet regimens.

What generic launch scenarios exist for EDARBYCLOR?

Scenario 1: Conventional ANDA launch

A sponsor uses a formulation close to the reference product, with mannitol, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate. This has the lowest development risk and the greatest price competition.

Scenario 2: Paragraph IV launch

A sponsor challenges remaining listed patents and seeks an early market position. The upside is higher gross margin and potential 180-day exclusivity if the statutory requirements are met. The downside is litigation cost, launch uncertainty, and possible settlement restrictions.

Scenario 3: Authorized-generic or licensed launch

A patent holder or licensee enters with a product aligned to the reference formulation. This can reduce patent exposure but may produce less margin and limited differentiation.

Scenario 4: Reformulated product

A company develops a smaller, more stable, or more rapidly dissolving tablet. This may support a 505(b)(2) strategy if the product includes a meaningful formulation change, but it would face greater clinical and regulatory requirements than a standard ANDA.[4]

What manufacturing and intellectual-property barriers remain?

The key manufacturing barrier is not access to the listed excipients. All major excipient classes are broadly available from multiple suppliers. The barriers are:

• Achieving uniform distribution of low-dose chlorthalidone
• Controlling azilsartan medoxomil dissolution
• Maintaining equivalence across four strengths
• Reproducing tablet performance at commercial scale
• Managing lubricant sensitivity
• Demonstrating stability under moisture and temperature stress
• Establishing freedom to operate around formulation and process claims

A supplier with a novel co-processed excipient or specialized solubility-enhancement platform could obtain stronger intellectual-property protection than a supplier offering conventional mannitol or cellulose. The patentable value would likely reside in a defined composition, ratio, particle-size distribution, process, or dissolution performance rather than in the excipient’s basic identity.

What is the revenue exposure and commercial value of EDARBYCLOR?

EDARBYCLOR’s revenue exposure is linked to the broader U.S. hypertension market, where generic substitution is intense. The commercial opportunity is strongest in:

• Supplying reference-product or generic-product excipients
• Licensing a formulation platform
• Developing an ANDA with an early-entry strategy
• Supporting a smaller-tablet or adherence-focused line extension
• Providing contract manufacturing for multi-strength tablets
• Creating co-packaged therapy programs

A conventional generic is likely to compete primarily on price and supply reliability. A differentiated formulation must demonstrate a tangible benefit, such as improved dissolution, reduced tablet burden, lower manufacturing cost, or better stability.

Key Takeaways

• EDARBYCLOR combines azilsartan medoxomil and chlorthalidone in four immediate-release strengths.
• Its core excipients are mannitol, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate.
• The principal formulation risks are azilsartan dissolution, chlorthalidone content uniformity, blend segregation, and magnesium stearate over-lubrication.
• Generic development is technically feasible with standard excipients, but strength-to-strength process control is critical.
• Excipient suppliers have the greatest opportunity with performance-grade materials, co-processed systems, and development support.
• A smaller tablet, solubility-enhanced product, or improved moisture-protection system could provide commercial differentiation.
• EDARBYCLOR’s five-year NCE exclusivity period has expired; current entry timing depends on listed patents, exclusivity, litigation, and settlement terms.
• The Orange Book and FDA patent listings should control all current patent and ANDA timing analyses.
• The most attractive commercial strategies are early generic entry, formulation licensing, CDMO supply, and high-performance excipient partnerships.

FAQs About EDARBYCLOR Excipients and Commercial Strategy

What is the most important excipient in EDARBYCLOR?

No single excipient controls the product. Crospovidone is important for disintegration and dissolution, while microcrystalline cellulose and mannitol control tablet structure and manufacturability.

Can EDARBYCLOR use lactose instead of mannitol?

A lactose-based formulation may be technically feasible, but it would require formulation, stability, dissolution, and bioequivalence evaluation. The substitution would not be commercially neutral.

Does EDARBYCLOR require a solubilizer?

The approved formulation is identified with conventional tablet excipients rather than a specialized solubilization system. A generic developer may evaluate a solubilizer, but it could affect dissolution, stability, and regulatory comparability.

Is EDARBYCLOR suitable for a 505(b)(2) product?

A 505(b)(2) pathway could be relevant for a materially reformulated or otherwise differentiated product. A standard equivalent tablet would generally be evaluated through the ANDA pathway.

Which excipient suppliers could benefit from EDARBYCLOR genericization?

Suppliers of direct-compression mannitol, microcrystalline cellulose, crospovidone, povidone, magnesium stearate, co-processed excipients, and moisture-barrier packaging materials are the most directly positioned.

References

1. U.S. Food and Drug Administration. (2011). EDARBYCLOR prescribing information. Takeda Pharmaceuticals USA, Inc.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA Center for Drug Evaluation and Research.